Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Thinly traded nano cap Alliqua BioMedical (ALQA) is up 28% premarket on light volume on the heels of its agreement to execute a reverse merger with private

Read more

Adynxx announced plans to merge with Alliqua BioMedical and become a Nasdaq-listed public company in early 2019 Company announced receipt of substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, a novel drug candidate intended to reduce both postoperative pain and the need for opioid-based therapies Company also announced plans to initiate two Phase 2 studies of brivoligide in postoperative pain with topline results expected in 2020 SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of pain and inflammatory diseases, today provided a business and clinical development update. Business Highlights and Recent Developments Adynxx entered into a merger agreement with Alliqua Biomedical, Inc. that will result in Adynxx becoming a Nasdaq-listed public company in early 2019. Immediately after the merger, the former Adynxx securityholders are expected to own approximately 86% of the combined company, and the existing stockholders of Alliqua are expected to own approximately 14% of the combined company.

Read more

Alliqua Biomedical (ALQA) are in focus as we look at near-term expected movement. The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is mainly used to identify ov

Read more

There are various types of investment philosophies that investors may choose to follow when approaching the stock market. Value investing involves searching for undervalued or bargain stocks that may

Read more

Shares of Alliqua Biomedical (ALQA) are on watch as the Tenkan Line has moved below the Kijun line, indicating negative momentum for the equity. Alliqua Biomedical moved -0.11 in the most recent sessi

Read more

Alliqua BioMedical, Inc. (NASDAQ:ALQA) decreased to $2.94. It was posted on Mar, 30 according to Barchart.com. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has

Read more

Investors looking to take advantage of cash heavy shares, they might look first to the cash flow of a company, and how fast that is growing. Alliqua BioMedical, Inc. (NasdaqCM:ALQA) currently has one

Read more

Two Sigma Securities LLC purchased a new position in shares of Alliqua Biomedical Inc (NASDAQ:ALQA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange

Read more

Stock analysis typically falls under the two main categories of fundamental and technical. Fundamental analysis involves diving into company financials. Fundamental analysts study how the company is p

Read more

Alliqua BioMedical, Inc. (NASDAQ:ALQA) has made the gainer list looking back over the past full-year. During that time period, shares have seen a bump of53.57%. Many investors will be watching to see

Read more

We will be contrasting the differences between Alliqua BioMedical Inc. (NASDAQ:ALQA) and ProPhase Labs Inc. (NASDAQ:PRPH) as far as analyst recommendations, profitability, risk, dividends, earnings an

Read more

Tracking the longer-term indicators on shares of Alliqua Biomedical (ALQA), we have noted that the 100-day moving average verse price signal is currently Buy. This is the signal from the 100-day MA wh

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank